Duchenne muscular dystrophy (DMD) is a fatal disorder caused by absence of functional dystrophin protein. Compensation in dystrophin-deficient (mdx) mice may be achieved by overexpression of its fetal paralogue, utrophin. Strategies to increase utrophin levels by stimulating promoter activity using small compounds are therefore a promising pharmacological approach. Here, we characterise similarities and differences existing within the mouse and human utrophin locus to assist in high-throughput screening for potential utrophin modulator drugs. We identified five novel 5'-utrophin isoforms (A', B',C,D and F) in adult and embryonic tissue. As the more efficient utrophin-based response in mdx skeletal muscle appears to involve independent transcriptional activation of conserved, myogenic isoforms (A' and F), elevating their paralogues in DMD patients is an encouraging therapeutic strategy.

Keywords: Duchenne muscular dystrophy; therapy; utrophin

Counteracting the absence of functional dystrophin in Duchenne muscular dystrophy (DMD) individuals via upregulation of its autosomal paralogue, utrophin [1], has been an appealing option for over two decades. The discovery and preliminary characterization of utrophin presented an ideal candidate to devise a replacement therapeutic strategy given its extensive protein sequence homology, size and functional properties with dystrophin, including association with the dystroglycan complex and F-actin [2–5]. Furthermore, developmental mouse (Utrn) and human (UTRN) transcription precedes that of dystrophin, and as such is considered a fetal precursor [6]. The latter is particularly evident during skeletal muscle development in mice and humans, where sarcolemmal Utrn/UTRN mRNAs rapidly decline upon dystrophin expression [7] resulting in postnatal confinement primarily to neuromuscular and myotendinous junctions [6,8,9]. Indeed, utrophin has been shown to physiologically rescue dystrophin-deficient mdx [10,11] mouse skeletal muscle by varied means, including transgenic upregulation, viral delivery and oral compound administration (reviewed in [12]). Consequently, discovery and exploitation of regulatory mechanisms that raise endogenous human utrophin mRNA levels are of great interest.

At the transcription level, two conserved, independently regulated utrophin promoters designated A [13] and B [14] transcribe full-length mRNAs that splice to exon 3 and differ only at their 5' ends (Fig. 1A). Postnatal A-utrophin protein localises to the adult neuromuscular junction, peripheral nerve and arterioles and, like dystrophin-deficient mdx mice, DMD patients frequently show retained postnatal sarcolemmal.
A-utrophin [15–17]. Given its upregulation and extrajunctional properties in mdx and to an extent in DMD striated muscle, UTRN-A is the favoured promoter-based therapeutic target for current strategies, as B-utrophin [17] remains restricted to endomysial capillaries and blood vessels [15,18].

Interestingly, the relatively mild mdx mouse phenotype appears conferred via postnatal mechanisms apparently absent in DMD patients, where limb muscle degeneration is effectively countered by reversion to fetal myogenic programming, including Utrn re-expression [19,20]. Furthermore, mice deficient in both full-length dystrophin and utrophin (dko) are a closer DMD phenocopy [21,22], implicating the regulatory control of utrophin in contributing to this mdx/DMD phenotypic disparity.

Given that the protein localization of A- and B-utrophin appears conserved within skeletal muscle [15–17], we postulated that mouse and human loci respond differently to counteract dystrophin deficiency by transcriptional regulation of alternative mRNA isoforms. We support this hypothesis by illustrating that novel, independently regulated transcripts are differentially regulated in the mdx mouse, and that conserved myogenic isoforms, in particular utrophin A and F, are valid screening targets for our small compound-mediated utrophin upregulation strategy. Importantly, this approach can be employed in methodologies to develop new therapeutic strategies for DMD patients.
targeting multiple isoforms or used in synergy with alternative therapeutic strategies to favour an enhanced regenerative response in DMD patients.

Materials and methods

RNA ligase-mediated (RLM) 5’ Rapid Amplification of cDNA Ends (5’RACE)

RLM-5’RACE (Ambion, Austin, USA) used 5 μg total decapped RNA from human (mix of 1.25 μg each of fetal heart/lung/thymus/skeletal muscle; Agilent, Santa Clara, USA) or mouse (mix of 2.5 μg each pooled whole embryo day 7 and 11; Clontech, Mountain View, USA). Reverse primers within utrophin exon 6 were used for cDNA synthesis (500 ng template) with 5’-outer adapter RACE primer for primary PCR (95 °C/1 min; 30 cycles 95 °C/45 s, 62 °C/45 s, 72 °C/1 min, final extension 72 °C/5 min). Secondary nested PCR (1/10 input) used 26 cycles with utrophin exon 4 reverse and 5’RACE forward adapter primers. Transcription start sites from PCR products were identified by cloning into a TA-vector (pCRII-TOPO; Invitrogen, USA) or mouse (mix of 2.5 μg each pooled whole embryo day 7 and 11; Clontech, Mountain View, USA) and normalising n = 60 individual colonies per species. Confirmation of novel utrophin transcripts used isoform-specific PCR (30 cycles, conditions as above). All PCR products were fully sequenced on both strands.

Quantitative/semiquantitative reverse transcription PCR (q/sqRT-PCR)

SYBR Green quantitative RT-PCR (qRT-PCR) used 1/20 cDNA template (1 μg total RNA input) synthesised from ≥2 different reverse primers within utrophin exons 4–6 (Table S1–S2) with 1/20 used in qRT-PCR. All reactions used Sensimix; Bioline, Ltd., Canton, MA, USA and Rotor-Gene 3000 (Corbett Life Science, Crawley, UK) with the exception of studies involving individual hindlimb muscle (Fig. S9; StepOne Real-Time system and Fast SYBR Green Master Mix; Thermo Fisher, Cramlington, UK). Values were obtained by comparison to primer set standard curves serially diluted 1 : 10 to adjusted length × (10 ng) and standardised to 28 s rRNA values from diluted cDNA template. Semiquantitative PCR (sqRT-PCR) for the human adult tissue RNA panel (Zyagen, Carlsbad, USA) used 32 cycles of 95 °C/45 s, 62 °C/45 s, 72 °C/1 min, final extension 72 °C/5 min and quantified using ImageQuant (Amersham Biosciences, Piscataway, USA).

Cell culture and tissue samples

Mouse C2C12 skeletal myoblast [23,24] and C3H/10T1/2 (C3H) pluripotent stem [25] cells were maintained in DMEM+10% FBS, 37 °C/5% CO₂. (C2C12: +2% horse serum (HS), C3H: +1 ng·mL⁻¹ recombinant human TGF-β1). H2K cells [26] were cultured in DMEM+20UmL⁻¹ γ-interferon, 2% chick embryo extract, 20% FBS at 33 °C/5% CO₂ and differentiated in DMEM+5% HS, 39 °C/5% CO₂ for 6 days. Human immortalised myoblasts [27] were cultured in F10 + 20% FBS at 37 °C/5% CO₂ and differentiated in 5% HS for 6 days. Cells were differentiated/harvested at 70–75% confluency. Male C57BL/10 wild-type and mdx [10,11] tissue was dissected, homogenised (Precells24; Bertin, Montigny-le-Bretonneux, France) and RNA isolated (Trizol; Invitrogen, Carlsbad, USA) according to manufacturers’ instructions. Pellets from clonal mesangioblast (MAB) cell lines D16 and D351 derived from the dorsal aorta of C57BL6 9.5 dpc embryos [28], isolated mdx embryonic aortic/postnatal skeletal muscle MABs and isolated DMD skeletal muscle MABs were a kind gift from G.Cossu and R.Tonlorenzi (San Raffaele Scientific Institute, Milan). Commercial sources of RNA are as follows: (a) mouse; Clontech, Mountain View, USA and (b) human embryo and adult tissue panel; Agilent Santa Clara, USA.

Luciferase constructs and reporter assays

The intersex region between mouse (640 bp) and human (728 bp) utrophin exons 1A and 1A’ (A⁶) were cloned in both orientations into the HindIII site of pGL4.10[luc2] (Promega, Madison WI, USA) and column-purified (Qiagen GmbH, Hilden, Germany). Mutagenesis of the mouse A⁶ E-Box (cagctg to ctgcgg) was performed as per [29]. C2C12 cells were seeded (7.5 × 10⁴ myoblast/3 × 10⁵ myotube) and transfected with 0.5 μg construct/20 ng pRL-TK control plasmid (Promega, Madison, USA) per 12 well. Luciferase activity was measured after 48 h on n = 8 separately transfected wells as previously described [30].

Electrophoretic mobility shift assay (EMSA)

EMSA was performed as outlined in [30] with 8 μg differentiation day 3 C2C12 nuclear extract or 10 μg human over-expression/control HEK293T lysate (OriGene, Rockville, USA). Assays employed 100-fold unlabelled probe (cold competitor) or 1 μg α-myogenin (F5D; sc-2027; Santa Cruz Biotechnologies, Santa Cruz, USA)/rabbit IgG added 30 min on ice prior to probe addition.

Antibody production and purification

F-utrophin antibody (“utroF”) was raised in two pathogen-free rabbits (denoted 74 and 75) by immunization with synthetic peptide to the unique mouse N terminus (MEET SVATDGASRES) coupled to keyhole limpet hemocyanin carrier protein via an additional C-terminal cysteine (Eurogentec, Southhampton, UK). Quality control during manufacture indicated utroF 74 and 75 antisera did not illustrate reactivity to preimmune serum and were functional in a peptide-based ELISA assay (Eurogentec, Southhampton,
UK). Antiserum immunoglobulin was precipitated by dissolving in 14%(w/v) anhydrous Na$_2$SO$_4$ (Sigma Aldrich, Poole, UK) at 37 °C/40 min, pelleted 2500 x g for 15 min, dissolved in $\frac{1}{2}$(v/v) H$_2$O and re-precipitated with 7%(w/v) anhydrous Na$_2$SO$_4$. Redissolved pellets (1xPBS) were affinity purified using immunising peptide immobilised on SulfoLink (Thermo Fisher, Cramlington, UK) as previously described [17].

**Immunoblotting**

Specificity of utroF was assessed by dot-blots of (a) serially diluted immunising peptide (2.0–0.02 µg) probed with utroA, B and F antibodies (1:200, 1:50 and 1:50 dilution in TBST+5% BSA respectively (Fig. S8c; left)) non-reactivity of utroF purified antiserum to utroB immunising peptide (Fig. S8c; right). All blots contained 20 µg total protein from 6-week $mdx$ tibialis anterior (TA) muscle as a positive control. Analysis of utroF control/$mdx$ 2-week diaphragm and 6-week TA (Fig. S8d) using utroF were performed under identical conditions and imaged using ImageQuant LAS 4000 (GE Healthcare Life Sciences, Little Chalfont, UK).

**Immunofluorescence**

Tissue sectioning and immunofluorescence (IF) was performed as described [31]. Polyclonal antibodies/dilutions are as follows: NCAM (C-20; 1:200), PCAM (MEC13.3; 1:500, Santa Cruz Biotechnology, Santa Cruz, USA), NG2 and αSMA (ab101679; 1:500 and ab21027; 1:250, Abcam, Cambridge, UK), utroA (1:2000), utroB (1:100) in 3% BSA (Sigma Aldrich, St Louis, USA). Secondary donkey antibodies used were: α-rabbit Alexa 488 (1:1000), α-rat Alexa 546 (1:1000, Molecular Probes, Leiden, Netherlands) and α-goat Alexa Cy3 (Thermo Fisher Scientific, Cramlington, UK; 1:1000). TA sections from 6-week $mdx$ mice were stained (300 mM ASPA) and imaged using Olympus FV1000 inverted Fluoview confocal microscopy/FV10-ASW software (Olympus Corp, Center Valley, USA). Confocal IF was also used to determine UtroF specificity using 6-week $mdx$ and $dko$ TA sections (Fig. S8) and use of secondary antibody-only controls. Analysis of specific skeletal muscle sections outlined in Fig. S9 used identical conditions as above, with α-rabbit Alexa 488 (1:2000) and imaged by upright fluorescence microscopy (Axioplan 2 Microscope System; Carl Zeiss, Germany).

**Sample numbers and statistical analysis**

sQRT-PCR (human tissue panel) was performed $n = 3$ per isoform using individually synthesised cDNA template mixes, quantified on separate agarose gels. All qRT-PCR reactions were conducted in triplicate, numbers as follows. C2C12 myogenesis and C3H studies were performed using cDNA synthesized from up to 4 or 6 wells, respectively (nonpooled), with standard deviation calculated if $n \geq 3$ separate cDNA preparations used. For prepooled samples (aorta-/skeletal muscle-derived $mdx$ mesoangioblasts, D16 and D351 clonal cell lines, mouse total embryo, human embryonic tissue), three separate cDNA preparations were performed in triplicate. Data presented in colour scale (Figs 1B–C, 2A–B) are presented in numerical form in Table S1–S2. Postnatal mouse tissue samples were extracted from $n \geq 3$ subjects; two tailed $t$-tests and $P$-values on data in Fig. 2A were conducted using Prism7 (GraphPad, La Jolla, USA) and listed in Table S2.

**Online database resources**

Sequence alignments were performed using NCBI BLAST (https://blast.ncbi.nlm.nih.gov[32]). Phylogenetic analysis of utrophin N-terminal peptide sequences used Clusal Omega [33]. Next-generation sequencing data from the University of Santa Cruz California (UCSC) genome browser/Encyclopedia of DNA Elements (ENCODE) aligned to mouse (NCBI37/mm9 assembly) and human (NCBI37/hg19) were accessed via http://genome-euro.ucsc.edu/, with data sources as follows: (a) mouse; DNaseI hypersensitivity site (HS) signals: University of Washington, C2C12 RNA-ChIP-seq data: Caltech (b) human; RNA-seq: Caltech, DNaseI HS raw/density signal: University of Washington and Duke University respectively; histone markers: Broad Institute [34,35].

**Animal use and ethics statement**

The source and use of animal tissue was performed under strict compliance with required standards outlined in the Animals (Scientific Procedures) Act 1986, revised 2012 (ASPA) and European Directive 63/2010 relating to the protection of animals for scientific purposes.

**Results**

Transcriptional complexity of mouse and human utrophin loci revealed by 5′RACE and genome analysis

As the genomic location and splicing configuration of utrophin A and B are conserved between mouse (Utrn) and human (UTRN) gene loci [13,14], we hypothesised unidentified novel regulatory transcripts/elements within the ~100 kb 5′ region spanning exons 1A-3 may contribute towards the $mdx$/DMD genotype-phenotype disparity. Novel exons were identified by 5′RACE using embryonic tissue, when utrophin expression peaks [8]. PCR products were cloned and
Fig. 2. Utrophin isoforms exhibit species- and isoform-specific transcript levels. (A) The postnatal mouse response to dystrophin-deficiency is tissue and isoform specific. Quantitative RT-PCR (qRT-PCR) analysis of tissue samples sourced from control (wt) C57BL/10 and mdx C57BL/10 mouse tissue at the 2-week precrisis period (upper panel) and during the degeneration-regeneration period in mdx during which total Utrn levels are elevated (6-weeks; lower panel). Values for wt are at the left and for mdx at the right as denoted below each pair of columns. Utrn-A/D mRNAs were greatly lowered in comparison to other isoforms (Table S2). *P* values represent differences between wild-type and mdx tissues at the same time point (*P* < 0.0001**, *P* < 0.001*, *P* < 0.05, 99% cll). qRT-PCR analysis of Utrn-A, A’ and -F levels in specific hindlimb muscles (tibialis anterior, quadriceps and soleus) compared to diaphragm (Fig. 2A) is provided in Fig. S9. (B) Selective upregulation of utrophin isoforms during C2C12 myogenesis, qRT-PCR analysis of endogenous Utrn mRNA levels in myoblasts (myob) and differentiating (dif) myotubes sampled at days 3, 6 and 9, with corresponding mRNA profiles illustrated below. For (A and B), values are represented as a colour scale under (B), standardised to 28s cDNA for each time-point. Numerical values obtained for all sample sets and additional statistical data are provided in Table S2. (C–D) Species-specific utrophin mRNA myogenic profiles are mirrored in skeletal muscle mesoangioblasts (MABs). qRT-PCR of utrophin mRNA isoform levels in wild-type, mdx/DMD myogenic cell lines (left panel; white columns, myoblast; black columns, myotubes as outlined in the legend) and in dystrophin-deficient skeletal muscle mesoangioblasts (MAB, grey columns, right panel). Values too low to be visualised by scale are provided numerically (upper value; myoblast, lower value; myotube). Numerical values for (A–B) sample sets are provided in Table S2.

Sequenced on both strands to determine transcription start sites. The presence of novel exons were then authenticated using isoform-specific RT-PCR, sequenced (Fig. S1–S4) and prefixed according to established nomenclature. Prime symbols (’) were allocated to exons that share sequences previously thought unique to previously identified full-length utrophin A- and B-mRNAs (A’ and B’ respectively, Fig. 1A).

Utrophin exon 1A’ lies in a conserved region ~ 550 bp 3’ to 1A and gives rise to *UtrnA’* mRNA (Fig. S1a) via coplicing to translated exon 2A. Thus, any protein product arising from utrophin 1A’ would be indistinguishable from utrophin 1A using mouse [17] and human [15] A-utrophin specific N-terminal antibodies. Conversely, utrophin B’ isoforms share a common first exon (1B), but divergent splicing results
in distinct open reading frames that retain actin-binding potential (Fig. S2). Three novel first exons splicing to exon 3 (1C,D and F) were also identified (Fig. 1A; Fig. S3–S4). As mouse exon 1C is untranslatable, potential use of an in-frame methionine in exon 4 would give rise to a protein indistinguishable using antibody-based approaches, whereas murine exon 1D contains two potential initiating methionines (Fig. S3). Human *Utrn*-C and *Utrn*-D paralogues were not detected, indicating these mRNAs are either (i) mouse-specific or (ii) absent in either the source tissue selected/within the conserved region selected for *UTRN*-specific 5‘RACE. In contrast, exon 1F was of particular interest; similar to exons 2A and 1B [17], *Utrn*-/*UTRN*-F mRNAs contain open-reading frames and have the capacity to encode unique N-terminal protein isoforms (Fig. S4). Identification of these novel mRNAs highlights the complexity of *Utrn/UTRN* loci, which differ in their splicing and transcriptional attributes.

**Utrophin isoforms are independently regulated in embryonic and adult tissues**

With the exception of *Utrn*-A’, developmental profiling indicates mouse *Utrn* transcription peaks at embryonic day 11 (Fig. 1B, Table S1) with subsequent decline concomitant with the onset of dystrophin transcription in smooth muscle (e11) and organs such as lung (e12) and brain (e13) [36,37]. During early embryogenesis (e7–11), utrophin 2A- and 1B-containing transcripts initially represent major isoforms, but become progressively less apparent when *Utrn* levels are lowest and the overall contribution from alternative mRNAs becomes more pronounced (e15–17; Fig. 1B). As total *UTRN* tissue patterning is similar to that of *Utrn*, we analysed the transcriptional attributes of human paralogues in embryonic and human tissue panels using qRT-PCR and sq-RT-PCR respectively (Fig. 1C, Fig. S5a, Table S1). Comparison of mRNAs that comprise total utrophin A (2A: *UTRN*-A/A’) or B (*UTRN*-B/B’) indicate that their individual mRNA transcripts have similar isoform-specific, but overall distinctive, expression profiles, a phenomenon previously indistinguishable by prior studies [13,14,17,38]. Although human utrophin isoforms appear independently regulated, common regulatory attributes may also be shared, particularly with *UTRN*-B/B’ where the main utrophin B’ mRNA start site lies within exon 1B (Fig. S2). Conversely, *UTRN*-F is particularly distinctive in its tissue specificity, with abundant distribution in mesenchymal lymphatic tissue and highly vascularised organs (Fig. 1C). The latter observation is solidified using UCSC ENCODE DNasel-seq data [34], where human exon 1F resides within an open chromatin region in not only embryonic stem cells, but in adult tissues; notably epithelial-derived cell lines (Fig. S6). Extending analysis to corresponding murine utrophin genomic regions, DNasel-seq data (Fig. S6–S7) indicates utrophin exons 1A,A’ and F all reside in open chromatin regions across a broad variety of embryonic and adult tissues.

**Postnatal *Utrn* mRNA variability in wild-type and *mdx* tissue**

We also wished to establish whether mouse utrophin transcript levels differ between age-matched wild-type and *mdx* tissue and thus performed isoform-specific qRT-PCR using tissue sourced at the preweaning stage (2 weeks) to determine transcript levels prior to increased activity and onset of visible muscle pathology. These data were directly compared to identical tissues isolated from 6-week old mice; after the primary ‘wave’ of muscle necrosis (3–4 weeks), when active regeneration, functional restoration and *Utrn* re-expression occurs [39,40](Fig. 2A). Postnatal *Utrn* is most abundant in lung [38,41,42] total *Utrn*-A and *Utrn*-B mRNA levels agree with prior studies [38]; and low levels of *Utrn*-C, D and F (Fig. 2A, Table S2) are comparable with wild-type mRNA profiles. We also assessed heart, given that cardiomyopathy represents a leading cause of DMD patient death [43]. *Utrn*-A and -B heart mRNAs are upregulated in *mdx* (1.7-fold), with total 1B-/2A-containing mRNA profiles similar to prior studies [14,17,38]. Other isoforms show comparable wild-type/*mdx* profiles that remain stable or decrease with age (Fig. 2A, Table S2). However, as *Utrn* overexpression in diaphragm ameliorates cardiac symptoms [44], the role of individual isoforms in perpetuating milder *mdx* cardiomyopathy was not pursued.

In diaphragm, the sole *mdx* tissue with severe DMD pathophysiology ([45]), utrophin A transcripts are markedly elevated in *mdx* at 6-weeks (*Utrn*-A; 2.9-fold and *Utrn*-A’; 3.2-fold, Fig. 2A, Table S2), mirrored to a lesser extent by *Utrn*-B (1.8-fold). Conversely, *Utrn*-B’ and -F upregulation in *mdx* at the 2 week stage is not retained. Surprisingly, elevated *Utrn*-F hindlimb levels in *mdx* at the preweaning stage (2.3-fold) almost doubles at 6-weeks (4.2-fold) representing a direct contrast to the concurrent, lower and nonsustained profile in diaphragm (Fig. 2A). As *Utrn*-A’/F upregulation may be linked to postnatal hindlimb regeneration in *mdx* [19,20], we wished to determine the myogenic capacity of *Utrn* isoforms for comparison with their human paralogues.
Myogenic upregulation of endogenous mouse utrophin mRNA in vitro

Links between *Utrn* and efficient postnatal mdx regeneration are established during reversion to fetal myogenic programming and muscle precursor activation [19,20,39,46]. We therefore initially documented levels of endogenous *Utrn* mRNAs during myogenic differentiation in C2C12 cells [23,24] and show *Utrn*-A (2.5-fold) and -A' (2.2-fold; Fig. 2B) contribute to the established 2-fold myogenic upregulation of 2A-containing mRNAs [30,38,47]. Furthermore, *Utrn*-C (1.4-fold) and *Utrn*-F (1.7-fold) mRNAs increase during myogenesis, whereas other isoform mRNAs were barely detectable. After consideration of the tissue and myogenic properties of novel transcripts, further characterization of murine utrophin isoforms B'/C/D were not pursued due to the absence of (a) a human parologue (b) an efficient myogenic response and (c) overall contribution to utrophin transcript levels in multiple tissues.

Utrophin isoforms exhibit species variability during myogenic differentiation

Although C2C12 cells represent an established myogenic model [23,24], they do not reflect the in vivo transcriptional decline of utrophin during skeletal muscle development [39,48] nor represent the absence of dystrophin. We therefore compared the transcriptional response of utrophin under wild-type and dystrophin-deficient conditions using immortalised cell lines from H-2Kb-tsA58 mice (H2K [26] Fig. 2C) and human skeletal muscle ([27] Fig. 2D). Although both systems recapitulate in vivo Utrn/UTRN myogenic profiles, two marked differences between species exist in conferring this response. The first is the ratio of 2A-containing mRNAs, where *Utrn*-A' mRNAs are more abundant in H2K-mdx than *UTRN*-A' in dystrophin-deficient hDMD cells. Secondly, a reciprocal relationship exists where elevated *Utrn*-F and low *Utrn*-B mRNA levels are reversed in their human paralogues. The impeded myogenic/dystrophic response of *UTRN*-A'/-F and expression of *UTRN*-B over human *UTRN*-F may be linked to differential myogenic signalling involving, in part, E-Box-mediated mechanisms.

The molecular basis of Utrn-A' and Utrn-F myogenic induction

As the mouse and human utrophin A myogenic response relies on a functional CANNTG E-Box motif (CAGCTG: [30]), we sought to establish if *Utrn*-A' transcription is dependent on the *Utrn*-A promoter, or is regulated by the uncharacterised 1A/1A' interexonic genomic region (*A'*) lying between exons 1A/1A' (Fig. 3 and Fig. S1). Analysis of the *A'* region using UCSC ENCODE-Caltech C2C12 ChiP-seq data [35] indicates extensive methylation (H3K4me2/3) and acetylation (H3K27ac) histone H3 marks that hallmark active transcription and positively acting regulatory regions (Fig. 3C), particularly in the absence of repressive H3K27me3 histone modifications [49,50]. Combined with additional ChiP- and RNA-seq data, this observation suggests the murine *A'* region is (a) recognised by myogenic factors (with particular affinity for myogenin containing complexes) specifically the E-box motif located proximal to the transcription start site of *Utrn*-A' and (b) produces mRNA levels commensurate with *Utrn*-1A (Fig. 3C). The corresponding human region was also assessed using UCSC ENCODE RNA- ChIP- and DNaseI-seq data [34,35] from wild-type LHCN-M2 [27] and HSMM immortalised skeletal muscle [51] cell lines (Fig. S6), indicating *UTRN*-1A' also resides in a region of open, transcriptionally active chromatin by DNAseI- and RNA-seq, the latter albeit at lower levels than *UTRN*-1A. Furthermore, as focal myogenic regulatory factor (myoD/myogenin) enrichment over *Utrn*-A/A' transcription start sites/E-Box motifs can be distinguished by intensity and differentiation-coupled increase, we postulated that the CAGCTG motif (a preferential hexamer for myogenin (myoG) and myoD [52]) within the mouse *A'* plays an important role in *Utrn*-A'-independent myogenic responsivity (Fig. 3B).

Given the location and preliminary characterization of the *A'*, numerous possibilities therefore exist in terms of its regulatory capability, including acting as an enhancer element, or driving transcription of an antisense transcript to exon 1A. Subsequent assessment of mouse and human utrophin *A* function using luciferase assays (Fig. 3A) indicates that both can function directionally to yield 1A' mRNAs (Fig. 3B), however, the myogenic response observed for mouse *A* (1.8-fold increase; compared to 2.1-fold for *Utrn*-A' mRNA; Fig. 3A) is not recapitulated in its human, nor E-Box mutant counterpart. This observation supports the hypothesis that the murine *A* E-Box can act as a myogenic element. Furthermore, as human utrophin A' exhibits endogenous myogenic activity (Fig. 2D), additional genomic elements residing outside the *A'* are clearly implicated in regulating this response.

Conversely, *Utrn*-F transcript levels in C2C12 myoblasts are lower compared to *Utrn*-A/A' (3.2/2.5-fold higher respectively) and increase at a later myogenic stage (d9: 1.7-fold, Fig. 2B). We thus employed a more direct, electrophoretic mobility shift assay (EMSA) using C2C12 nuclear extracts to establish the functional
The utrophin interexonic region (A1') facilitates myogenic induction of Utrn-A1'. (A) The mouse and human utrophin A1' illustrate the capacity to function as A1' promoter elements. Comparison between transfected C2C12 myoblasts (myob) and 3-day differentiated myotubes (diff3) lysates indicate myogenic upregulation of Utrn-A1' (a compromised in the mouse E-Box mutant (ΔE-Box; grey columns) and (b) absent in the human equivalent. Luciferase constructs are detailed on the left and results represented in grey-scale per graph legend (right). Error bars; SD, samples = 8 separately transfected wells/time point. (B) Mouse (upper) and human (lower) sequence alignment spanning the 3rd end of Utrophin 1A to the splice donor site of Utrophin 1A'. Location of murine E-Box (black), transcription start sites of Utrn/UTRN-1A' (black arrows; transcribed sequence in bold) and HindIII sites used to clone the interexonic region as denoted. Splice junctions to exon 2A are marked with arrows. (C) Utrophin exon 1A/1A' genomic region aligned with UCSC ENCODE-Caltech C2C12 ChIP-seq and RNA-seq data [34,35]. Arrows; transcription start sites, untranslated exons (black boxes) and E-N-Box motifs (grey boxes), A1' region aligned to UCSC tracks (dashed box). Scale bar provided. MyoD/myogenin 24/60 h differentiation, and active histone (H3K4me2/3; H3K27ac) marks are as denoted on the left of each track. myob, myoblast; myoc, myocyte; Additional DNAsel-, RNA- and ChIP-seq data encompassing the mouse and human 1A/1A' region is provided in Fig. S6.

Fig. 3. The utrophin interexonic region (A1') facilitates myogenic induction of Utrn-A1'. (A) The mouse and human utrophin A1' illustrate the capacity to function as A1' promoter elements. Comparison between transfected C2C12 myoblasts (myob) and 3-day differentiated myotubes (diff3) lysates indicate myogenic upregulation of Utrn-A1' (a compromised in the mouse E-Box mutant (ΔE-Box; grey columns) and (b) absent in the human equivalent. Luciferase constructs are detailed on the left and results represented in grey-scale per graph legend (right). Error bars; SD, samples obtained from n = 8 separately transfected wells/time point. (B) Mouse (upper) and human (lower) sequence alignment spanning the 3rd end of Utrophin 1A to the splice donor site of Utrophin 1A'. Location of murine E-Box (black), transcription start sites of Utrn/UTRN-1A' (black arrows; transcribed sequence in bold) and HindIII sites used to clone the interexonic region as denoted. Splice junctions to exon 2A are marked with arrows. (C) Utrophin exon 1A/1A' genomic region aligned with UCSC ENCODE-Caltech C2C12 ChIP-seq and RNA-seq data [34,35]. Arrows; transcription start sites, untranslated exons (black boxes) and E-N-Box motifs (grey boxes), A1' region aligned to UCSC tracks (dashed box). Scale bar provided. MyoD/myogenin 24/60 h differentiation, and active histone (H3K4me2/3; H3K27ac) marks are as denoted on the left of each track. myob, myoblast; myoc, myocyte; Additional DNAsel-, RNA- and ChIP-seq data encompassing the mouse and human 1A/1A' region is provided in Fig. S6.

capability of the conserved Utrn-/UTRN-F E-Box motif (Fig. 4B). Interestingly, mouse and human 1F promoter regions have different affinities for myogenic factor-containing complexes to UTRN-A [30], including myoD and myoG. It is tempting to speculate that the unique UTRN-A protein complex represents myoD homodimers, as the Utrn-/UTRN-F CAGTTG motif illustrates preference for heteromeric myoG-E12 and MyoD-E2A complexes [53]. This would account for weakened human UTRN-F probe binding in comparison to mouse (despite identical core hexamers; Fig. 4B) as heterodimerised complexes are particularly reliant on flanking nucleotides for affinity [53].

F-utrophin distribution overlaps A- and B-utrophin in mdx skeletal muscle

Similar to 2A- and 1B-containing mRNAs, exon 1F potentially encodes a unique N-terminal full-length utrophin protein (Fig. 4, Fig. S4). Given the potential of F-utrophin to contribute to regeneration/sarcolemmal stabilization of mdx skeletal muscle, we sought to
Utraphin isoforms augment the mdx/DMD phenotype

K. J. Perkins and K. E. Davies

identify where resultant protein is localised, particularly as prior studies indicate that total utrophin can be accounted for by A-utrophin and -B only [17]. Although not shared by a common utrophin isoform, we confirmed the putative N-terminal peptide encoded by exon 1F is wholly discrete from A-utrophin and -B using multiple sequence alignment and phylogenetic analysis (Fig. 4A). Previous studies indicate that total utrophin can be used for EMSA (electrophoretic mobility shift assay) probes; red amino acids denote the peptide sequence used to generate the utrophin murine antibody (utroF) and splice junction to exon 3 is marked with an arrow (canonical intronic splice donor dinucleotide italised). (B: left) Utrn/UTRN-F E-Box motifs indicate distinct protein binding affinity and complex formation from UTRNA using differentiation day 3 mouse C2C12 nuclear extracts. (B: middle) EMSA analysis using anti-myogenin (anti-myog) antibody and day 3 differentiated cells (‘extract’) with Utrn-F probe (‘probe’) indicates myoG-containing complexes. (B: right) Mouse and human utrophin F E-Box regions have the capacity to bind myoD and myoG as evidenced using human overexpression and control cell lysate. The UTRNA E-Box is provided as a positive control. DNA:protein complex type is indicated by arrows (specific; white, non-specific; black, absence; grey) and addition of antibody by circles (myogenin; black, IgG control; white). ±: addition/absence of labelled components, Probe: radiolabelled double-stranded probe, extract; 8 µg nuclear extract, cc mt/wt; 100 x excess cold mutant/wild-type E-Box competitor, myog/myoD: myoG/myoD overexpression lysate, lysate: control lysate. Panels (C-F): U-traphin distribution in tibialis anterior (TA) muscle. Dual-labelled confocal microscopy of 6-week mdx sections using antibodies to F-utrophin (utroF, left; green), indicated markers (middle, red) and merged images (right; DAPI staining, blue). Interstitial muscle niche localization (E: inset) noted. Scale bars as indicated. Data on utroF specificity (Fig. S8) and immunofluorescence/qRT-PCR data profiling mouse utrophin control cell lysate. The Mouse and human utrophin F E-Box regions have the capacity to bind myoD and myoG as evidenced using human overexpression and (anti-myoG) antibody and day 3 differentiated cells (‘extract’) with Utrn-F probe (‘probe’) indicates myoG-containing complexes. (B: right) Mouse and human utrophin F E-Box regions have the capacity to bind myoD and myoG as evidenced using human overexpression and control cell lysate. The UTRNA E-Box is provided as a positive control. DNA:protein complex type is indicated by arrows (specific; white, non-specific; black, absence; grey) and addition of antibody by circles (myogenin; black, IgG control; white). ±: addition/absence of labelled components, Probe: radiolabelled double-stranded probe, extract; 8 µg nuclear extract, cc mt/wt; 100 x excess cold mutant/wild-type E-Box competitor, myog/myoD: myoG/myoD overexpression lysate, lysate: control lysate. Panels (C-F): U-traphin distribution in tibialis anterior (TA) muscle. Dual-labelled confocal microscopy of 6-week mdx sections using antibodies to F-utrophin (utroF, left; green), indicated markers (middle, red) and merged images (right; DAPI staining, blue). Interstitial muscle niche localization (E: inset) noted. Scale bars as indicated. Data on utroF specificity (Fig. S8) and immunofluorescence/qRT-PCR data profiling mouse utrophin F in specific skeletal muscles (Fig. S9) is provided in Supporting information.
respectively [17]. Similar to prior results using A-utrophin antibody [17], F-utrophin is present in the tunica media, evidenced by colocalization with \(\alpha\)-smooth muscle actin, and discrete from the B-utrophin containing endothelial layer (established using marker PCAM/CD31; Fig. 4D). Incomplete overlap in UtroF/PCAM microvessel staining indicates that F-utrophin is present in pericytes embedded within the basement vessel membrane. Furthermore, regional colocalization of UtroF within immature muscle fibres and the interstitial endomysium was observed with neuron-glial factor-2 (NG2): staining myogenic pericytes such as mesoangioblasts (MABs: [54,55]) and NCAM, a reliable index of \(mdx\) regenerating tissue [56,57], illustrates that F-utrophin has the capability to participate in the perivascular-driven myofibre regenerative process. We confirmed our observations by performing additional immunofluorescence on 6-week TA and other skeletal muscle sections (quadriceps, soleus and diaphragm), including wild-type controls (Fig. S9b). Interestingly, concurrent qRT-PCR analysis (Fig. S9a) demonstrated that Utrn-F reflects previously determined total \(Utrn\) transcript levels [58] and utrophin A in particular [59,60] by being higher in wild-type slow, oxidative muscle (soleus; 3.1-fold) compared to those predominately consisting of fast fibres (TA). This tissue difference was more marked comparing \(mdx\) soleus and TA (12.9-fold, 3.4-fold and 8.8-fold for Utrn-1A, -A’ and -F respectively). Furthermore, the difference between \(mdx\) over control \(Utrn-F\) mRNA levels illustrated the same trend (3.8-fold in soleus compared to 1.3-fold in TA). We thus establish that mouse F-utrophin not only shares nonsarcolemmal attributes previously attributed solely to A- and B-utrophin, but may be regulated by regenerative mechanisms influenced by oxidative capacity.

**Utrphoin mRNAs in perivascular mesenchymal stem cells parallel species-specific myogenic profiling**

Given the localization of F-utrophin and its species-specific dystrophic response at the mRNA level appear myogenic, we also wished to determine if this phenomena could be linked to vessel-derived muscle regeneration. Vascular-derived mesenchymal precursors potentiate myogenic regeneration in diseased muscle [54,55]. In particular, the mesoangioblast (MAB) pericytic subset can restore dystrophin-deficient muscle and thus represent an attractive DMD stem cell-therapy approach ([61], for review [62]).

As F-utrophin appears perivascular, we monitored utrophin mRNAs during transforming growth factor \(\beta1\) (TGF-\(\beta1\)) induced lineage differentiation of the mouse C3H10T1/2 *in vitro* model (C3H; [25]) into smooth muscle [63,64] (Fig. S5b) and in wild-type MAB cell lines established from embryonic mouse dorsal aorta (D351 and D16 [28]; Fig. S5c). Utrphin 2A mRNAs were upregulated during C3H differentiation (~2-fold), particularly at 48 hrs when \(\alpha\)SMA expression is highest [63-65]. Commensurate with this, D351 Utrn-A/A’ mRNA elevation over D16 MABs (Fig. S5c) matches total \(Utrn\) array data in pericytes [65] and supports that 2A-mRNAs positively respond to smooth-muscle signalling, as D351 are further progressed down this lineage than D16 [28]. Conversely, Utrn-F appears independent of TGF-\(\beta1\)-related signalling and is preferentially expressed in cells retaining pluripotency (Fig. S5b-c).

Links between lineage preference and dystrophic *Utrn* upregulation ability were then assessed using wild-type/mdx aortic MABs. Direct comparison using cells representing different stages of pluripotency proved complex, as *Utrn-A/F* transcripts were elevated; however, unlike *Utrn-A*, high D351 *Utrn-A’* levels did not further increase in \(mdx\) MABs isolated directly from aorta (Fig. S5c). We thus specifically compared \(mdx\) and DMD MABs sourced from skeletal muscle, which not only recapitulated differences between \(UTRN/Utrn\) transcript levels and ratios observed between dystrophin-deficient myoblasts, but were more pronounced, particularly in DMD MABs (Fig. 2C,D). This furthers our hypothesis that mouse and human loci have evolved separate, possibly myogenic, strategies in response to dystrophin deficiency.

**Discussion**

Utrophin is regarded as a regeneration-associated protein, as its expression is linked to effective myogenic re-programming that enables functional restoration of \(mdx\) skeletal muscle. In the \(mdx\) mouse model, postnatal *Utrn* re-expression is hallmark by upregulation within the sub-sarclemma and vascular perimysium, a compensatory mechanism that correlates with DMD disease severity but without the protective effects observed in \(mdx\) mice (reviewed in [66,67]). As dystrophin-utrophin (dko) knockout mice are a more accurate reflection of the DMD phenotype [21,22], our hypothesis was that the mouse utrophin locus possesses a transcriptional response to dystrophic conditions that differs from its human equivalent. We therefore focused on the isolation of mouse (*Utrn*) and human (*UTRN*) utrophin transcripts with novel S’ sequences and characterising their transcriptional and species-specific attributes. Encouragingly, the observed
enhanced capability in mdx appears to be conferred by differential regulation of Utrn isoforms with human paralogues, rather than solely murine-specific mRNAs.

First, this phenomenon is manifest for utrophin A [13] and B [14] which this study identifies both as two independently regulated mRNAs (A/A’ and B/B’). The 2A-containing transcripts share myogenic attributes; however, their independency is marked by preferences for Utrn-A'/UTRN-A upregulation during dystrophin-deficient myogenesis, and within myogenic stem cells such as MABs. Myogenic E-Box mediated mechanisms within the mouse Aβ may elevate levels of extrajunctional Utrn-A' mRNA that can contribute to sarcomemal A-utrophin protein in mdx. This phenomena is possibly compromised in DMD patients given the absence of an E-Box in the human Aβ region. Importantly, however, both DMD myoblasts and MABs exhibit the presence of myogenically responsive UTRN-A’ (albeit at lower levels), suggesting elements outside the Aβ are likely to confer positive mediation of myogenic signalling or increase post-transcriptional stability. The role of 1B exon derived isoforms appears more complex. Although UTRN-B' illustrates similarities in its transcriptional profile with its shared exon 1B counterpart (UTRN-B), the lack of myogenic capability, coupled with nonconserved splicing/putative translation attributes, indicates that an UTRN-B'-derived strategy is unlikely to be translated to human benefit.

Secondly, we identify a novel transcript, utrophin F, which demonstrates such marked regulatory differences between mouse and humans that we immediately considered its transcriptional control as a primary utrophin candidate in modulating the mdx phenotype. Indeed, Utrn-F is the sole non-2A-containing transcript upregulated in mdx skeletal muscle, during in vitro myogenesis and within MABs to levels unparalled by its DMD paralogue. Links between Utrn-F and enhanced mdx regeneration were provided by robust transcriptional upregulation in regeneration-competent hindlimb (particularly soleus), that is absent in regeneration-inhibited diaphragm. Using confocal microscopy, we localised F-utrophin protein with regeneration-rich regions in mdx skeletal muscle, including immature myofibres and the interstitial endomysium, where mesenchymal-lymphocyte mediated regeneration occurs [68]. This region contains multipotent vascular-derived/mesenchymal precursors with myogenic potential such as pericytes and MABs with increased Utrn levels [65,68] and assist, incorporate or even form, myofibres (reviewed in [55]). Our hypothesis that Utrn-F is linked to these events is further bolstered by preferential transcription in mesenchymal cells that retain pluripotency, and upregulation in mdx MABs. Critically, as Utrn-F does not appear to be directly regulated via TGF-β1-inducible pathways, upregulation within the myofibre niche is unlikely to induce fibrosis or inhibit vital regenerative processes such as satellite cell proliferation, myofibre fusion or muscle-specific gene transcription, a hurdle that currently prevents direct TGF-β1 targeting strategies from entering the clinic. Isolation of Utrn-A/-F thus allows development of a novel upregulation strategy linked to the vascular-derived regeneration process to combat nonsarcolemmal DMD pathology.

Dissecting transcriptional and genomic properties of established and novel isoforms alike, we illustrate the utrophin locus displays a considerably more complex pattern of transcriptional regulation and interspecies variation than previously expected. Encouragingly, utrophin A and F isoforms exhibiting desirable upregulation traits in mouse (such as the ability to respond to myogenic and regenerative stimuli) have independently regulated human paralogues, providing novel pharmacological targets to supplement promoter-based small compound approaches focussed on UTRN-A. We thus envisage that a multitargeting utrophin upregulation approach has therapeutic promise in countering sarcolemmal and nonsarcolemmal pathology within DMD skeletal muscle.

**Acknowledgements**

N. Proudfoot (Sir William Dunn School of Pathology, Oxford); Laboratory Supervision, S. Squire, B. Edwards, L. Moir, A. Berg, A. Potter, D. Powell, R. Fairclough; mice, antibody purification, preliminary dot blot analysis (Department of Physiology, Anatomy and Genetics, Oxford). G. Cossu, R. Tonlorenzi (San Raffaele Scientific Institute, Milan); mesangioblasts, J. Morgan (Imperial College, London); H2K cells, V. Mouly, A. Goyenvalle (Institut de Myologie, Paris); human myoblast cell lines. H. Dugdale (Department of Physiology, Anatomy and Genetics, Oxford); manuscript suggestions. This study was supported by Muscular Dystrophy UK, Medical Research Council UK, Edward Penley Abraham Research Fund and an Association Française contre les Myopathies (AFM) Postdoctoral Fellowship.

**Author contributions**

KJP conceptualised and performed experiments, analysed and interpreted data; KED supervised the study, provided experiment advice, and assisted with data interpretation. KJP wrote the manuscript, KED and KJP made manuscript revisions.
References

1 Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH and Davies KE (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. *Nature* **339**, 55–58.

2 Pearce M, Blake DJ, Tinsley JM, Byth BC, Campbell L, Monaco AP and Davies KE (1993) The utrophin and dystrophin genes share similarities in genomic structure. *Hum Mol Genet* **2**, 1765–1772.

3 Winder SJ, Hemmings L, Bolton SJ, Maciver SK, Tinsley JM, Davies KE, Critchley DR and Kendrick-Jones J (1995) Calmodulin regulation of utrophin actin binding. *Biochem Soc Trans* **23**, 397S.

4 Winder SJ, Hemmings L, Maciver SK, Bolton SJ, Tinsley JM, Davies KE, Critchley DR and Kendrick-Jones J (1995) Utrophin actin binding domain: analysis of actin binding and cellular targeting. *J Cell Sci* **108**, 63–71.

5 Coulton GR, Curtin NA, Morgan JE and Partridge TA (1988) The mdx mouse skeletal muscle myopathy: II. Contractile properties. *Neuropathol Appl Neurobiol* **14**, 299–314.

6 Clerk A, Morris GE, Dubowitz V, Davies KE and Sewry CA (1993) Dystrophin-related protein, utrophin, and dystrophin genes share similarities in genomic structure. *Nature* **366**, 554–561.

7 Prell A, Chianese L, Moggio M, Gallanti A, Sciacco M, Checcharelli N, Comi G, Scarpini E, Bonilla E and Scarlato G (1991) Appearance and localization of dystrophin in normal human fetal skeletal muscle. *Int J Dev Neurosci* **9**, 607–612.

8 Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, Fardeau M, Kaplan JC and Kunkel LM (1991) Immunolocalization and development of dystrophin related protein in skeletal muscle. *Neuromuscul Disord* **1**, 185–194.

9 Pons F, Nicholson LV, Robert A, Voit T and Leger JJ (1995) Utrophin actin binding domain: analysis of actin binding and cellular targeting. *J Cell Sci* **108**, 63–71.

10 Bullfield G, Siller WG, Wight PA and Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. *Proc Natl Acad Sci USA* **81**, 1189–1192.

11 Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG and Barnard PJ (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. *Science* **244**, 1578–1580.

12 Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ and Kunkel LM (2015) The pathogenesis and therapy of muscular dystrophies. *Annu Rev Genomics Hum Genet* **16**, 281–308.

13 Dennis CL, Tinsley JM, Deconinck AE and Davies KE (1996) Molecular and functional analysis of the utrophin promoter. *Nucleic Acids Res* **24**, 1646–1652.

14 Burton EA, Tinsley JM, Holzfeind PJ, Rodrigues NR and Davies KE (1999) A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. *Proc Natl Acad Sci USA* **96**, 14025–14030.

15 Sewry CA, Nowak KJ, Ehmsen JT and Davies KE (2005) A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours. *Neuromuscul Disord* **15**, 779–785.

16 Pons F, Robert A, Marini JF and Leger JJ (1994) Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency? *J Neurol Sci* **122**, 162–170.

17 Weir AP, Burton EA, Harrod G and Davies KE (2002) A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. *J Biol Chem* **277**, 45285–45290.

18 Weir AP, Morgan JE and Davies KE (2004) A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. *Neuromuscul Disord* **14**, 19–23.

19 Anderson JE, Bressler BH and Ovalle WK (1988) Functional regeneration in the hindlimb skeletal muscle of the mdx mouse. *J Muscle Res Cell Motil* **9**, 499–515.

20 Coulton GR, Morgan JE, Partridge TA and Sloper JC (1988) The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. *Neuropathol Appl Neurobiol* **14**, 53–70.

21 Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM and Davies KE (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. *Cell* **90**, 717–727.

22 Deconinck N, Rafael JA, Beckers-Bleukx G, Kahn D, Deconinck AE, Davies KE and Gillis JM (1998) Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. *Neuromuscul Disord* **8**, 362–370.

23 Yaffe D and Saxel O (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature* **269**, 725–727.

24 Yaffe D and Saxel O (1977) A myogenic cell line with altered serum requirements for differentiation. *Differentiation* **7**, 159–166.

25 Reznikoff CA, Brankow DW and Heidelberger C (1973) Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. *Cancer Res* **33**, 3231–3238.
Partridge TA (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. *Dev Biol* 162, 486–498.

Zhu CH, Mould V, Cooper RN, Mammachou K, Bigot A, Shay JW, Di Santo JP, Butler-Browne GS and Wright WE (2007) Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. *Aging Cell* 6, 515–523.

Brunelli S, Tagliafico E, De Angelis FG, Tonlorenzi R, Baesso S, Ferrari S, Niinobe M, Yoshikawa K, Schwartz RJ, Bozzi A (2007) Mdx2 and nevadin combined activities are required for smooth muscle differentiation in mesoangioblast stem cells. *Circ Res* 94, 1571–1578.

Perkins KJ, Lusic M, Mitar I, Giacca M and Proudfoot NJ (2008) Transcription-dependent gene looping of the Msx2 and nevadin expression system. *Nucleic Acids Res* 36, 4843–4850.

Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R, Gillis JM and Davies KE (2002) Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. *Hum Mol Genet* 11, 3333–3344.

Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215, 403–410.

Sievers F and Higgins DG (2018) Clustal Omega for making accurate alignments of many protein sequences. *Protein Sci* 27, 135–145.

Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, Goldman M, Barber GP, Clawson H, Coelho A et al. (2011) The UCSC Genome Browser database: update 2011. *Nucleic Acids Res* 39, D876–D882.

Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, Raney BJ, Wang T, Hinrichs AS, Zweig AS et al. (2010) ENCODE whole-genome data in the UCSC Genome Browser. *Nucleic Acids Res* 38, D620–D625.

Houzelstein D, Lyons GE, Chamberlain J and Buckingham ME (1992) Localization of dystrophin gene transcripts during mouse embryogenesis. *J Cell Biol* 119, 811–821.

Schofield J, Houzelstein D, Davies K, Buckingham M and Edwards YH (1993) Expression of the dystrophin-related protein (utrophin) gene during mouse embryogenesis. *Dev Dyn* 198, 254–264.

Baby SM, Bogdanovich S, Willmann G, Basu U, Lozynska O and Khurana TS (2010) Differential expression of utrophin-A and -B promoters in the central nervous system (CNS) of normal and dystrophic mdx mice. *Brain Pathol* 20, 323–342.

Roma J, Munell F, Fargas A and Roig M (2004) Evolution of pathological changes in the gastrocnemius of the mdx mice correlate with utrophin and beta-dystroglycan expression. *Acta Neuropathol* 108, 443–452.

Willmann R, Possek S, Dubach-Powell J, Meier T and Ruegg MA (2009) Mammalian animal models for Duchenne muscular dystrophy. *Neuromuscular Disord* 19, 241–249.

Matsumura K, Shasby DM and Campbell KP (1993) Purification of dystrophin-related protein (utrophin) from lung and its identification in pulmonary artery endothelial cells. *FEBS Lett* 326, 289–293.

Matsumura K, Yamada H, Shimizu T and Campbell KP (1993) Differential expression of dystrophin, utrophin and dystrophin-associated proteins in peripheral nerve. *FEBS Lett* 334, 281–285.

Fayssois A, Nardi O, Orlikowski D and Annane D (2010) Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. *Heart Fail Rev* 15, 103–107.

Crisp A, Yin H, Goyenvalle A, Betts C, Moulton HM, Seow Y, Babbs A, Merritt T, Saleh AF, Gait MJ et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. *Hum Mol Genet* 20, 413–421.

Fairclough RJ, Bareja A and Davies KE (2011) Progress in therapy for Duchenne muscular dystrophy. *Exp Physiol* 96, 1101–1113.

Grady RM, Merlie JP and Sanes JR (1997) Subtle neuromuscular defects in utrophin-deficient mice. *J Cell Biol* 136, 871–882.

Gramolini AO and Jasmin BJ (1999) Expression of the dystrophin gene during myogenic differentiation. *Nucleic Acids Res* 27, 3603–3609.

Furst DO, Osborn M and Weber K (1989) Myogenesis in the mouse embryo: differential onset of expression of myogenic proteins and the involvement of titin in myofibril assembly. *J Cell Biol* 109, 517–527.

Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA et al. (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat Genet* 39, 311–318.

Lund AH and van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. *Curr Opin Cell Biol* 16, 239–246.

Hussain KM, Lee RC, Ng MM and Chu JJ (2016) Establishment of a novel primary human skeletal...
myoblast cellular model for chikungunya virus infection and pathogenesis. Sci Rep 6, 21406.

52 Londhe P and Davie JK (2011) Sequential association of myogenic regulatory factors and E proteins at muscle-specific genes. Skelet Muscle 1, 14.

53 Blackwell TK and Weintraub H (1990) Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science 250, 1104–1110.

54 Cossu G and Bianco P (2003) Mesoangioblasts–vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev 13, 537–542.

55 Cossu G and Biressi S (2005) Satellite cells, myoblasts and other occasional myogenic progenitors: possible origin, phenotypic features and role in muscle regeneration. Semin Cell Biol 16, 623–631.

56 Capkovic KL, Stevenson S, Johnson MC, Thelen JJ and Cornelison DD (2008) Neural cell adhesion molecule (NCAM) marks adult myogenic cells committed to differentiation. Exp Cell Res 314, 1553–1565.

57 Dubois C, Figarella-Branger D, Pastoret C, Rampini C, Karpati G and Rougon G (1994) Expression of NCAM and its polysialylated isoforms during mdx mouse muscle regeneration and in vitro myogenesis. Neuromuscul Disord 4, 171–182.

58 Gramolini AO, Belanger G, Thompson JM, Chakkalakal JV and Jasmin BJ (2001) Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am J Physiol Cell Physiol 281, C1300–C1309.

59 Chakkalakal JV, Miura P, Belanger G, Michel RN and Jasmin BJ (2008) Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. Nucleic Acids Res 36, 826–838.

60 Chakkalakal JV, Stockles MA, Harrison MA, Angus LM, Deschenes-Furry J, St-Pierre S, Megenev LA, Chin ER, Michel RN and Jasmin BJ (2003) Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci USA 100, 7791–7796.

61 Sampaolesi M, Blot S, D’Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthelemy I et al. (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574–579.

62 Berry SE (2015) Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions. Stem Cells Transl Med 4, 91–98.

63 Hirschi KK and D’Amore PA (1996) Pericytes in the microvasculature. Cardiovasc Res 32, 687–698.

64 Hirschi KK, Rohovsky SA and D’Amore PA (1998) PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141, 805–814.

65 Kale S, Hanaj I, Chan B, Karihaloo A, Grotendorst G, Cantley L and Sukhatme VP (2005) Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J 19, 270–271.

66 Goyenvalle A, Seto JT, Davies KE and Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20, R69–R78.

67 Khurana TS and Davies KE (2003) Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2, 379–390.

68 Liu Y, Wang L, Kikui T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S and Shi S (2011) Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17, 1594–1601.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article:

Fig. S1. Mouse and human sequence alignment of utrophin exon 1A and 1A’ genomic region.

Fig. S2. Mouse and human sequence alignment of utrophin exon 1B and 1B’ genomic region.

Fig. S3. Mouse and human sequence alignment of utrophin exon 1C and 1D genomic regions.

Fig. S4. Mouse and human sequence alignment of utrophin exon 1F genomic region.

Fig. S5. Data on utrophin isoforms to accompany Figs 1 and 2.

Fig. S6. Additional information provided by UCSC ENCODE Data.

Fig. S7. UCSC DNAseI-seq information for mouse and human utrophin 1F.

Fig. S8. F-utrophin N-terminal sequence and specificity of UtroF antibody.

Fig. S9. Utrophin F transcript levels and protein distribution in skeletal muscle.

Table S1. Utrn/UTRN qRT-PCR and sqRT-PCR values to accompany Fig. 1.

Table S2. Utrn qRT-PCR values and statistics to accompany Fig. 2.